Page last updated: 2024-11-03

ro 31-8220 and Carcinogenesis

ro 31-8220 has been researched along with Carcinogenesis in 1 studies

Ro 31-8220: a protein kinase C inhibitor

Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.

Research Excerpts

ExcerptRelevanceReference
"ErbB2 overexpression drives oncogenesis in 20-30% cases of breast cancer."1.40A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. ( Ahmad, G; Bailey, TA; Band, H; Band, V; Bielecki, TA; George, M; Kelly, DL; Luan, H; Mohapatra, B; Natarajan, A; Raja, SM; Tom, E, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bailey, TA1
Luan, H1
Tom, E1
Bielecki, TA1
Mohapatra, B1
Ahmad, G1
George, M1
Kelly, DL1
Natarajan, A1
Raja, SM1
Band, V1
Band, H1

Other Studies

1 other study available for ro 31-8220 and Carcinogenesis

ArticleYear
A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
    The Journal of biological chemistry, 2014, Oct-31, Volume: 289, Issue:44

    Topics: Antineoplastic Agents; Benzoquinones; Breast Neoplasms; Carbazoles; Carcinogenesis; Cell Line, Tumor

2014